Search
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[A264199] Upon administration, PTH is cleaved from palopegteriparatide in a controlled manner to achieve a continuous systemic exposure of active PTH. … Palopegteriparatide is a parathyroid hormone (PTH) analog.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleVibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigational[L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency, … [L28310] Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigational[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: O-desmethylvenlafaxineNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33359] Nirmatrelvir is advantageous in that it can be prescribed to patients before they require hospitalization, while [PF-07304814] requires intravenous administration in hospital. … [A234224,A234229,A234234] In 2020, Pfizer was investigating another potential treatment for SARS-CoV-2, [PF-07304814].
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesOpicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine … Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsViomycin
go.drugbank.com/drugs/DB06827ApprovedViomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. … These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_.
Synonyms: Vinacetin AEnsifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigationalEnsifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. … [L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be
Synonyms: N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREA, UREA, N-(2-(6,7-DIHYDRO-9,10-DIMETHOXY-4-OXO-2-((2,4,6-TRIMETHYLPHENYL)IMINO)-2H-PYRIMIDO(6,1-A)ISOQUINOLIN-3(4H)-YL)ETHYL)-Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingGaretosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic … Garetosmab-grts is an activin A inhibitor used to treat fibrodysplasia ossificans progressiva (FOP).
Cedazuridine
go.drugbank.com/drugs/DB15694ApprovedInvestigational[A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by … Astex Pharmaceuticals Inc under the name INQOVI®.
Synonyms: (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridineCategories: Heterocyclic Compounds, 1-RingPegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigationalPhenylketonuria is a rare autosomal recessive disorder that is characterized by deficiency of the enzyme phenylalanine hydroxylase (PAH) [A33284] and affects about 1 in 10,000 to 15,000 people in the United … Individuals with PKU also need to be under a strictly restricted diet as Phe is present in foods and products with high-intensity sweeteners [L2925].